These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7863623)

  • 1. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.
    Uemura Y; Yang YH; Heldebrant CM; Takechi K; Yokoyama K
    Vox Sang; 1994; 67(3):246-54. PubMed ID: 7863623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.
    Chandra S; Cavanaugh JE; Lin CM; Pierre-Jerome C; Yerram N; Weeks R; Flanigan E; Feldman F
    Transfusion; 1999 Mar; 39(3):249-57. PubMed ID: 10204586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
    Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chikungunya virus and the safety of plasma products.
    Leydold SM; Farcet MR; Kindermann J; Modrof J; Pölsler G; Berting A; Howard MK; Barrett PN; Kreil TR
    Transfusion; 2012 Oct; 52(10):2122-30. PubMed ID: 22339168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Viral safety considerations in immunoglobulin preparations].
    Gómez Manzano P; Escrivá CA; Salmerón García F; Alonso Verduras C
    Sangre (Barc); 1997 Jun; 42(3):199-203. PubMed ID: 9381262
    [No Abstract]   [Full Text] [Related]  

  • 9. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
    Roberts PL; Dunkerley C; Walker C
    Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and Sindbis viruses) from an intravenous immunoglobulin preparation.
    Hamamoto Y; Harada S; Yamamoto N; Uemura Y; Goto T; Suyama T
    Vox Sang; 1987; 53(2):65-9. PubMed ID: 2825431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
    Lebing W; Remington KM; Schreiner C; Paul HI
    Vox Sang; 2003 Apr; 84(3):193-201. PubMed ID: 12670368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
    Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
    Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.
    Morgenthaler JJ; Omar A
    Dev Biol Stand; 1993; 81():185-90. PubMed ID: 8174802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses.
    Hilfenhaus J; Gröner A; Nowak T; Weimer T
    Transfusion; 1997 Sep; 37(9):935-40. PubMed ID: 9308641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
    Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
    Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus validation studies of immunoglobulin preparations.
    Biesert L
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S47-52. PubMed ID: 8828948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.